Arkema SA (ARKAY) – What Are Researchers Saying About This Stock?

Shares of Arkema SA (OTCMKTS:ARKAY) have received a consensus recommendation of “Reduce” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a hold recommendation on the company.

A number of brokerages have commented on ARKAY. Barclays upgraded shares of Arkema from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Arkema in a research note on Tuesday, June 23rd.

Arkema Stock Down 2.1%

ARKAY opened at $60.38 on Tuesday. Arkema has a 12 month low of $56.28 and a 12 month high of $79.36. The business has a 50-day moving average of $67.16 and a two-hundred day moving average of $67.80. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.52 and a quick ratio of 1.08. The stock has a market capitalization of $4.59 billion, a price-to-earnings ratio of 208.20 and a beta of 0.88.

Arkema (OTCMKTS:ARKAY) last released its quarterly earnings data on Thursday, July 30th. The basic materials company reported $1.98 EPS for the quarter, topping analysts’ consensus estimates of $1.86 by $0.12. Arkema had a return on equity of 4.30% and a net margin of 0.67%. The business had revenue of $2.79 billion during the quarter, compared to the consensus estimate of $2.86 billion. On average, research analysts expect that Arkema will post 3.73 earnings per share for the current year.

Arkema Company Profile

Arkema is a France-based specialty materials company that develops and manufactures materials used in a broad range of industrial and consumer applications. Its portfolio includes high-performance polymers, adhesives, coating materials, additives and specialty chemical intermediates.

The company’s businesses serve markets such as construction, automotive, electronics, renewable energy, consumer goods, packaging and healthcare. Arkema’s brands and product lines include Bostik adhesives, Kynar fluoropolymers, Rilsan polyamide materials, Pebax elastomers and Sartomer specialty resins and additives.

Arkema was established in 2004 through the reorganization of Total’s chemicals businesses and became an independent, publicly traded company in 2006.